Turning public approval data into dashboards for portfolio strategy Turning public approval data into dashboards for portfolio strategy In the ever-evolving landscape of pharmaceutical and biotech industries, competitive intelligence derived from drug approval packages is not just a strategic necessity but an operational imperative. Regulatory Affairs professionals play a pivotal role in leveraging the wealth of publicly available approval data, such as Drugs@FDA, European Public Assessment Reports (EPARs), and Summary Basis of Approval (SBA), to create informative dashboards that aid in portfolio strategy development. Regulatory Affairs Context Regulatory Affairs (RA) encompasses the oversight of the processes through which pharmaceuticals are…

Combining Patent, Label and Approval Data for End-to-End CI Views Combining Patent, Label and Approval Data for End-to-End CI Views in Regulatory Affairs In the pharmaceutical and biotechnology sectors, regulatory professionals must navigate a complex landscape of guidelines and regulations. One essential aspect of this landscape is the gathering and analysis of competitive intelligence (CI) from drug approval packages, such as the Summary Basis of Approval (SBA) and European Public Assessment Reports (EPAR). This article provides a comprehensive guide on how to effectively combine patent, label, and approval data to achieve a holistic view of competitive landscape. Regulatory Affairs Context…

Leveraging Advisory Committee Briefing Packages for Competitor Insights Leveraging Advisory Committee Briefing Packages for Competitor Insights The highly competitive landscape of the pharmaceutical and biotechnology sectors necessitates not only innovation but also astute regulatory strategies. Knowledge of the competitive intelligence derived from drug approval packages, particularly advisory committee briefing packages, is pivotal for regulatory affairs professionals. This article aims to provide a comprehensive manual detailing the intricacies of these regulatory submissions and how they can be leveraged for informing competitive strategies. Context Advisory committees play a critical role in the drug approval process, particularly in the United States under the…

Governance for compliant use of regulatory competitive intelligence Governance for Compliant Use of Regulatory Competitive Intelligence Context In the highly regulated pharmaceutical and biotechnology sectors, competitive intelligence plays a critical role in strategic decision-making. Regulatory competitive intelligence refers to the systematic gathering and analysis of information regarding regulatory submissions, product approvals, and market trends to inform product development and market strategy. It encompasses the evaluation of drug approval packages, summary basis of approval documents, and post-market surveillance data. Understanding how to navigate the regulatory landscape while leveraging this intelligence is essential for professionals within Regulatory Affairs (RA) teams, especially when…

Global Extensions of CI Using EMA EPARs and Other Agency Reports Global Extensions of CI Using EMA EPARs and Other Agency Reports In the realm of pharmaceutical and biotech development, understanding the competitive landscape is essential for regulatory affairs professionals. This article will serve as a detailed guide, exploring how global competitive intelligence (CI) can be enhanced through the use of drug approval packages, particularly focusing on EMA’s European Public Assessment Reports (EPARs) and other relevant agency documentation. Context of Competitive Intelligence in Regulatory Affairs Competitive intelligence in the pharmaceutical industry entails collecting and analyzing information to enhance strategic decision-making…